Gongwin Biopharm, which develops human anticancer new drugs with "minimally invasive targeted tumor ablation technology", has recently obtained approval from the Bureau of Animal and Health Plant Health Inspection and Quarantine, Council of Agriculture, to include National Taiwan University Veterinary Hospital and MSAH Animal Hospital to be its clinical implementation teams of GWA101 new anti-cancer drugs, making advance deployment for future domestic sales channels.
Gongwin-KY pointed out that in November last year, it obtained the first domestic approval form the Bureau of Animal and Health Plant Health Inspection and Quarantine, Council of Agriculture, to implement field pre-trial for fur babies’ cancer treatment. The case acceptance for malignant melanoma, soft tissue sarcoma, squamous cell carcinoma (SCC), liver cancer and benign lipoma was launched at 4 animal hospitals including Evergreen, WellcareVet, Aurora, and TZUOO-ANN. This participation of the National Taiwan University Veterinary Hospital affirmed the company's efforts in the development of new cancer drugs for animals.
In a report published on "Pet Cancer Therapeutics Market—Growth, Trends, and Forecast (2019-2024)" by ResearchandMarkets in November 2019, the total market value of the US pet health care market in 2019 is estimated to be US$ 75.38 billion. Among them, the cancer treatment for companion dogs will be the most significant market trend setter in the next 5 years.
Following the completions of research and development results on companion animal cancer treatments, one after another, Gongwin-KY is preparing to publish the research results within 3 months to allow the outside world to verify the feasibility of the "Minimally Invasive Targeted Tumor Ablation Technology" in canine/cat companion animal cancer treatment market.
News link URL：https://tw.appledaily.com/property/20201113/LTSALJCTHZAHLBU57FE6UP2TAM/
News&Media